Episodic Migraine
Pipeline by Development Stage
Drug Modality Breakdown
Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.
Key Trends
- Extreme market concentration: 68% of spending driven by one FXa inhibitor product
- Psychiatric and migraine therapies emerging as secondary growth drivers
- High clinical trial activity (8,279 trials) signals continued pipeline development
Career Verdict
Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 68% | Launch | Stable | 15.0yr |
| 2 | INVEGA SUSTENNA (paliperidone palmitate) | Johnson & Johnson | $1.8B | 7% | Peak | Stable | 4.7yr |
| 3 | BRILINTA (ticagrelor) | AstraZeneca | $692M | 3% | Peak | Stable | 10.2yr |
| 4 | NUPLAZID (pimavanserin tartrate) | Acadia Pharmaceuticals | $596M | 2% | Peak | Stable | 10.9yr |
| 5 | INVEGA TRINZA (paliperidone palmitate) | Johnson & Johnson | $530M | 2% | Peak | Stable | 15.5yr |
Drug Class Breakdown
market-defining single product
stable mature class
niche but stable
specialty indication focus
emerging growth segment
stable with LOE risk
diverse small products
Career Outlook
StableNeurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.
Breaking In
Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.
For Experienced Professionals
Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.
In-Demand Skills
Best For
Hiring Landscape
Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.
Top Hiring Companies
By Department
Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.
On Market (1)
Approved therapies currently available
Competitive Landscape
12 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 18 trials with date data
Clinical Trials (18)
Total enrollment: 9,556 patients across 18 trials
Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients
A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies
DFN-11 Injection in Episodic Migraine With or Without Aura
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
Cerebri Biofeedback Feasibility Trial
Evaluation of Peripheral Nerve Stimulation for Acute Treatment of Migraine Pain
Related Jobs in Neurology
Contract-Materials Handler
Machine Learning Scientist — Agentic data pipelines
Security Officer I (Saturday - Tuesday, 6:30 am – 5:00 pm shift)
Executive Assistant to Chief Medical Officer (CMO)
P&C Government Relations Partner
Learning Specialist
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.